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Abstract 
Purpose: Lifestyle-related conditions such as obesity are associated with prostate cancer progression, but the 
link with hyperglycemia and dyslipidemia is unclear. This study, therefore, aims to explore how glucose, 
triglycerides and total cholesterol are associated with prostate cancer death. 
 
Methods: From the Swedish AMORIS cohort, we selected 14150 men diagnosed with prostate cancer between 
1996 and 2011 who had prediagnostic measurements of serum glucose, triglycerides and total cholesterol. 
Multivariable Cox proportional hazards models were used to determine the hazard ratios for death in relation 
to the aforementioned metabolic markers adjusting for potential confounders. 
 
Results: Using clinical cut-off points, a non-significant positive association was observed between glucose and 
prostate cancer death. When compared to those with glucose in the lowest quartile, those in the highest quartile 
had greater risk of prostate cancer death (HR: 1.19; 95% CI: 1.02-1.39). However, neither total cholesterol nor 
triglycerides were associated with prostate cancer death. Glucose and triglycerides were positively associated 
with overall, cardiovascular and other deaths. Hypercholesterolemia was only associated with risk of CVD 
death.  
 
Conclusion: Our results suggest that glucose levels may influence prostate cancer survival, but further studies 
using repeated measurements are needed to further elucidate how glucose levels may affect prostate cancer 
progression.  
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Introduction 
Prostate cancer is a leading cause of deaths among men globally (1), which, according to epidemiological 
studies, may be partly due to lifestyle-related factors (2,3). For instance, a recent study demonstrated that 
incidence of lethal prostate cancer was higher among men with poorer lifestyle habits characterised by high 
intake of energy-dense foods, high alcohol intake, physical inactivity and smoking (4). In line with this, 
several epidemiological studies reported that life-style related conditions such as metabolic syndrome and 
obesity were associated with increased risk of prostate cancer death (2,5,6). Other metabolic disorders 
including hyperglycemia and dyslipidemia have also been associated with lower survival for other types of 
cancers such as breast, colorectal and pancreatic cancer, but research on their associations with prostate 
cancer death is sparse and inconclusive (2,7-10).  
 
Moreover, experimental evidence purports that glucose and lipid aberrations trigger prostate cancer 
progression by inducing carcinogenic processes such as cell proliferation and growth, inflammation, and 
DNA damage. One study reported that  hyperinsulinemia, a phenotype of diabetes, increases levels of 
circulating free bioactive insulin growth factor (IGF-1) by inhibiting the secretion of IGF binding protein-1 
(IGFBP-1) and SHBG resulting in tumor cell growth, proliferation and migration (11,12). Similarly, 
dyslipidemia has been implicated with altering signalling pathways, including PTEN and PI3K/AKT, which 
control cell proliferation, and migration (13).  
 
To provide greater insight into the role that metabolic disturbances may play in relation to prostate cancer 
progression, in this study, we investigated the associations between pre-diagnostic serum glucose, 
triglycerides and cholesterol and prostate cancer death among men with prostate cancer. We also conducted 
stratified analyses by prostate cancer risk category and competing risk analyses to assess the potential effects 
of competing events on our findings.  
 
Materials and Methods  
Study design and population 
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A detailed description of the Swedish Apolipoprotein MOrtality RISk (AMORIS) cohort has been published 
elsewhere (14,15). Briefly, the database included 812,073 Swedish men and women with blood samples 
which were assessed at the Central Automation Laboratory (CALAB) in Stockholm, Sweden, during the 
period 1985 to 1996 (16-18). Individuals enrolled in the study were primarily from the greater Stockholm 
area and, were either healthy and having laboratory testing as part of a general health check or outpatients 
referred for laboratory testing. None of the participants were inpatients at the time of sampling. The CALAB 
data was linked to several Swedish national registries including the Swedish National Cancer Register, the 
Hospital Discharge Register, the Cause of Death Register, the consecutive Swedish Censuses during 1970-
1990, and the National Register of Emigration using the Swedish 10-digit personal identity number (REF).  
 
For the present analysis, the AMORIS cohort was linked to the National Prostate Cancer Register (NPCR), 
which has been nationwide since 1998 (19). This Register, which includes 98% of all newly diagnosed 
prostate cancer cases registered in the Swedish National Cancer Register to which reporting is mandated, 
aims to provide data for quality assurance  (19) . We retrieved information on date of diagnosis, age at 
diagnosis, pathological TNM stage, Gleason score and serum concentration of PSA at time of diagnosis from 
the NPCR (16). We utilise information on TNM stage, Gleason score, and serum concentration of PSA at 
time of diagnosis to generate the prostate cancer risk category which was defined in accordance with an 
adapted version of National Comprehensive Cancer Network as low risk (T1-2, Gleason score 2–6 and PSA 
<10 ng/ml), intermediate risk (T1-2, Gleason score 7 and/or PSA 10 to <20 ng/ml), high risk (T3 and/or 
Gleason score 8–10 and/or PSA 20 to <50 ng/ml), and regionally metastatic tumors (T4 and/or N1 and/or 
PSA 50 to <100 ng/ml in the absence of distant metastases (M0 or MX)) and distant metastatic tumors (M1 
and/or PSA >100 ng/ml) (19). Information on educational level was abstracted from the Population and 
Housing Census for 1970-1990 while information on the participants' comorbidity status was abstracted from 
the National Patient Register. Using information on the participants' status, we calculated the Charlson 
Comorbidity Index which includes 19 diseases, with each disease category assigned a weight. We then 
totalled the weights to create a score which was categorised into four levels (0, 1, 2, and ≥3), and ranged 
from no co-morbidity to severe co-morbidity (20). 
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Men were excluded from this study if they did not have any information on PSA levels, Gleason grade, and 
TNM stage (n= 5995) or if their glucose, total cholesterol and triglycerides measurements were not taken at 
the same health examination (n= 2991). After exclusion, our study comprised 14,150 men aged 20 and older 
with a primary prostate cancer diagnosis between 1996 and 2011 (Figure I). 
 
Pre-diagnostic serum levels of glucose, triglycerides and total cholesterol were our main exposures. For the 
purpose this study we selected the most recent serum measurement which was taken approximately 14 years 
prior to diagnosis. Serum levels of glucose, total cholesterol and triglycerides were determined enzymatically 
(21) using fully automated systems with automatic calibration (17). All analyses were done at an accredited 
laboratory (17). 
 
For our analyses, serum glucose, total cholesterol and triglycerides levels were classified based on clinical 
cut-off points from the American Diabetes Association and National Cholesterol Education Programme 
(NCEP) guidelines (22-24), and as quartiles. For the clinical cut-off points, serum glucose levels were 
categorised as <5.6mmol/l, 5.6-6.9mmol/l and >6.9mmol/l, while serum total cholesterol was classified as 
<5.18mmol/l, 5.18mmol/l-6.19mmol/l, and >6.19mmol/l and serum triglycerides as <1.7mmol/l, 1.7-
2.24mmol/l, and >2.24mmol/l. The lowest clinical cut-off points and quartiles were selected as the reference 
category.  
 
The outcome of interest was prostate cancer death. To assess the role of competing risks, we also included 
overall, cardiovascular (CVD) and other deaths as outcomes. Prostate cancer death was defined using ICD-
10 code C61. Cardiovascular death was defined using ICD-10 codes I0-I78, while death from other causes 
included all deaths except prostate cancer and CVD deaths. 
 
The study complied with the Declaration of Helsinki and was approved by the Ethics Review Board of the 
Karolinska Institute. 
 
Statistical analysis 
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Cox proportional hazards regression was conducted to calculate the hazard ratios (HR) and 95% confidence 
intervals (95% CI) for the association between serum glucose, total cholesterol and triglycerides and deaths 
(overall, prostate cancer, CVD and other) with age as the underlying timescale. Participants were followed 
from age at diagnosis of primary prostate cancer to age at death from any cause, emigration or end of study 
(December 31st, 2011), whichever came first.  
 
In multivariable analyses, our main models were adjusted for age at diagnosis (as a quadratic function), 
educational level (low- (primary school or less), intermediate (high school), high-(higher education)), CCI 
(0, 1, 2, ≥3), fasting status (fasting, non-fasting), and mutually adjusted for serum glucose (continuous), total 
cholesterol (continuous) and triglycerides (continuous) (model 1). For prostate cancer death, we additionally 
adjusted for prostate cancer risk category (low risk, intermediate risk, high risk, regional metastatic, distant 
metastatic, missing) in separate analyses. We also conducted stratified analyses by prostate cancer risk 
category to assess the differences in the association between the serum markers and prostate cancer death 
within strata of the prostate cancer risk category. Tests for interaction between the markers and prostate 
cancer risk category were assessed using the Wald test.  
 
We used Schoenfeld residuals to test the proportional hazards assumption; there was no evidence to suggest 
that the assumption was violated.  
 
To evaluate the shape of the relation between the continuous exposures (glucose, triglycerides and total 
cholesterol) and prostate cancer death, glucose, triglycerides and total cholesterol were modelled by two-
tailed restricted cubic splines with four knots of the distribution in a Cox proportional hazards regression 
model (25).  
 
Hyperglycemia and dyslipidemia are strongly associated with overall mortality (26,27). Hence, we used the 
Fine and Gray competing-risks regression to account for the potential effect of competing risks on our 
findings, whereby CVD deaths and other deaths were considered as competing events (28). As inclusion of 
men with non-fasting serum measurements may affect the estimates, we also conducted a sensitivity analysis 
including only men with fasting measurements to evaluate the association between the metabolic markers 
7 
 
and death. In order to examine whether latent cancer might have affected the exposure measurements, we 
excluded the first 2 years of follow-up from our analyses. Body mass index (BMI) is associated with both the 
exposure measurements and prostate cancer death and may be an important confounder in our study. 
However, BMI could not be included as a covariate in our multivariable analyses due to the high proportion 
of missing information on BMI (78.5%). In subgroup analyses among men with information on BMI 
(n=3,073), which was taken at the same time with blood draw (i.e. least 14 years prior to diagnosis), we 
adjusted for BMI to assess its effect on the association between the metabolic markers and death. Missing 
values were considered as a separate category in the statistical models. 
 
Data management was conducted with Statistical Analysis Software (SAS) release 9.4 (SAS Institute, Cary, 
NC), while statistical analyses were conducted with Stata release 13.1 and 14.1 (StataCorp, College Station, 
TX, USA).  
 
Results  
Mean age at prostate cancer diagnosis in the study population was 68 (standard deviation (SD) = 8.0) years 
(Table 1). Approximately 1/3 of men were diagnosed with low risk prostate cancer. Among the 3,223 men 
who died during a mean follow-up time of approximately 4 years, 1,473 died from prostate cancer.  Most 
men had at least a high school education . Mean serum concentrations for glucose, triglycerides and total 
cholesterol were 5.1mmol/l, 1.5mmol/l and 5.9mmol/l, respectively. Generally, the study characteristics for 
those who were excluded from the study were similar to those who were included in the study (Table S1). 
 
Glucose 
After adjusting for age, educational level, CCI, fasting status, triglycerides and total cholesterol, we observed 
that men with glucose levels in the pre-diabetic and diabetic range had increased risk of prostate cancer death 
(HR: 1.15; 95% CI: 1.00-1.32 and 1.29; 1.00-1.67 for glucose levels of 5.6-6.9mmol/L and >6.9mmol/L 
respectively; p for trend: 0.01) (Table 2). The statistically significant trend disappeared after additional 
adjustment for prostate cancer risk category. When considering quartiles of glucose level, men with glucose 
in the highest quartile had a higher risk of prostate cancer death than those in lower quartile (HR: 1.27; 95% 
CI: 1.09-1.48; p for trend: <0.01). The association was further attenuated after additional adjustments for 
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prostate cancer risk category but remained statistically significant (HR: 1.19; 95% CI: 1.02-1.39; p for trend: 
0.04). The association between glucose and prostate cancer death, however, did not differ by prostate cancer 
risk categories (p for interaction: 0.21) (Table 4). Glucose was also positively associated with overall death, 
and other deaths based on both the clinical cut-off points and quartiles (Table 2). Men with high glucose 
levels (>6.9mmol/L) defined by clinical cut-off points also had an increased risk of CVD death.  
 
In a restricted cubic spline model, our finding demonstrated no evidence of a non- linear association between 
glucose and prostate cancer death (p for non-linearity=0.83) (Figure 2).  
 
Triglycerides  
When considering the clinical cut-off points and quartile distribution, triglycerides was not associated with 
prostate cancer death in multivariable analyses (Table 2). In analyses stratified by prostate cancer risk 
category, similar null findings for the association between triglycerides and risk of prostate cancer death was 
seen (p for interaction: 0.37) (Table 4). Triglycerides, however, was positively associated with overall, CVD 
and other deaths irrespective of the cut-off points used (Table 2). There was no evidence a non-linear 
association between triglycerides and prostate cancer death (p for non-linearity= 0.33) (Figure 2).  
 
Total cholesterol  
Total cholesterol was not associated with prostate cancer death overall, or when stratified by prostate cancer 
risk category (p for interaction: 0.21) (Tables 2 and 4). There was also no association between total 
cholesterol and overall and other deaths. However, based on clinical cut-off points, hypercholesterolemic 
men (>6.19 mmol/L) had higher risk of CVD death than those with normal cholesterol levels 
(<5.18mmol/L). Similar positive associations were seen for quartiles of total cholesterol. 
 
 There was no evidence of a non-linear association between total cholesterol and prostate cancer survival (p 
for non-linearity 0.36) (Figure 2).  
 
Sensitivity analyses 
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After excluding men with non-fasting measurements, the directions of the associations between metabolic 
markers and prostate cancer death virtually remained the same (Tables S2). Similarly, in analyses where we 
excluded the first 2 years of follow-up, the directions of the associations remained unchanged. In competing 
risk analyses, the estimates using Fine and Gray competing risk regression and Cox proportional hazards 
models were not materially different (Table S3). Finally, in analyses involving a subgroup of men with 
information on BMI, the directions of the associations did not vary substantially following inclusion of BMI 
as a covariate in the fully adjusted model (Table S4).  
 
Discussion 
In this large prospective study, we observed a weak positive association between serum levels of glucose and 
prostate cancer death, but no associations were observed for triglycerides and total cholesterol. Glucose and 
triglycerides were positively associated with overall, CVD or other deaths. Hypercholesterolemia was also 
positively associated with CVD death.  
 
Glucose 
Consistent with other studies we found positive associations between glucose and prostate cancer death 
(10,29). Other studies yielded non-significant associations between diabetes and prostate cancer death, but 
the associations were positive in most of these studies (30-32). Although, previous epidemiological studies 
provide evidence suggesting that the severity of the disease may modify the effect of risk factors which 
potentially influence prostate cancer progression  on prostate cancer survival (5,33), in the current study, we 
did not observe any modifying effect of the severity of the disease on the association between glucose and 
prostate cancer death.   
 
Obesity, which is associated with glucose aberrations and prostate cancer death (5,6,12), may also partly 
explain the observed positive association between glucose and prostate cancer death, but the inclusion of 
BMI in our multivariate models had virtually no effect - suggesting that BMI is not an important confounder 
in our study. 
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In line with our findings, metformin, an antidiabetic drug, has been shown to improve prostate cancer 
survival (34). Other studies using in vivo and in vitro models also demonstrated that glucose metabolism 
contributes to prostate cancer progression by inducing tumor cell proliferation, survival and migration 
(35,36). For instance, one study found that a diet high in refined carbohydrates promoted tumor growth by 
increasing IGF-1 levels and activating Akt signalling pathway in mice (36).  
 
Triglycerides 
To date, very few studies have investigated the association between triglycerides and prostate cancer death. 
Similar to our study, two small studies found non-significant positive associations between triglycerides and 
prostate cancer death (37,38). In contrast, another study reported a non-significant inverse association 
between triglycerides and prostate cancer-specific death (32).  
 
Despite the lack of association between triglycerides and prostate cancer in the present study, experimental 
studies suggest that triglycerides may induce prostate cancer progression. For instance, several studies have 
shown that triglyceride-rich remnant like particles induced PC-3 cell proliferation by upregulating pathways 
such as MEK/ERK and/or Akt pathways, which are responsible for regulating cancer-associated processes 
including cell growth and proliferation, and cell cycle arrest (39,40). 
 
Total cholesterol 
Similar to the HUNT 2 study, we did not find any association between total cholesterol and prostate cancer 
death in the overall study population (32). Interestingly, though, the findings based on quartiles of total 
cholesterol and our spline model suggested a non-significant inverse association between total cholesterol 
and prostate cancer death. Haggstrom et al. also reported an inverse, but non-significant, association between 
total cholesterol and prostate cancer death (8). This finding may be due to the influence of latent cancer. 
However, in analyses where we excluded the first two years of follow-up, the tendency remained.  
 
Although epidemiological studies, so far, do not support an association between total cholesterol and prostate 
cancer survival, an association between total cholesterol and prostate cancer survival cannot be negated as 
evidence from experimental studies has associated this exposure with mechanisms which are known to 
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induce progression of cancer.  Intervention studies, for example, showed that statins inhibit prostate cancer 
development and progression by suppressing the enzyme HMG-CoA reductase and hence de novo 
steroidogenesis (41,42). Further, one recent study showed that cholesterol increased activity of TRMP7 
resulting in activation of AKT and/or the ERK pathway and increased proliferation of prostate cells (43). 
Other studies indicated that a hypercholesterolemic diet induced prostate cancer development and 
progression in mice (44,45).  
 
Competing risk 
Prostate cancer is a disease which primarily affects the older men (46) who are also at greater risk of 
developing metabolic-related comorbidities such as cardiovascular diseases that may alter a man’s 
probability of dying from the cancer itself (47,48). In this regard, several studies, including the present study, 
have implicated abnormal glucose, triglycerides, and total cholesterol levels with increased risk of overall, 
CVD and/or other deaths (10,27,49). Such competing events can contribute to underestimation of the 
associations between metabolic markers and prostate cancer death. However, the findings from our 
competing risk analyses imply that the presence of these events had virtually no effect on the association 
between the metabolic markers and prostate cancer death in the present study.  
 
Strengths and limitations 
One of the main strengths of this study is its relatively large sample size. Furthermore, our study population 
was selected from a population-based prostate cancer register with very high completeness. Furthermore, all 
exposure measurements were taken prior to diagnosis at the same laboratory; thereby allowing us to assess 
associations between the exposures and outcomes temporally. This study, however, has several limitations. A 
limitation of this study is the lack of repeated measurements for the metabolic markers which are known to 
have high intra-person variability. It is therefore likely that our study did not detect the true association 
between the exposures and the outcomes since we were unable to assess the cumulative effect that changes in 
the exposures over time, due to factors such as lifestyle changes and medication use, may have on the 
outcome. Although, the relatively long-time window between measurement of the exposure and date of 
diagnosis was another limitation of the present study, prostate cancer is a slow-growing disease which, 
according to autopsy studies, can be initiated as early as 20s and 30s in many men (50). Hence, our study 
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may reflect the fact that metabolic factors in the early progression phase may influence the natural history of 
the disease, and should be further investigated in future studies using repeated measures. It is also probable 
that misclassification of the exposures may have occurred as the participants’ medication history (i.e. history 
of use of metformin and/or statin) or diabetic status was unknown, but the misclassification will most likely 
be non-differential. Finally, we did not have information on lifestyle-related behaviours such as smoking 
status and dietary history, but neither smoking nor diet is an established risk factor for prostate cancer death.  
 
Conclusion 
Our findings support a positive but weak association between glucose and prostate cancer death. Our study 
also confirmed that this exposure, as well as triglycerides and total cholesterol, are important predictors of 
overall deaths and/or CVD deaths. Taken together, our findings provide support for the hypothesis that 
improved metabolic control by means of lifestyle changes or pharmacological treatment may contribute to 
improving survival in men with prostate cancer. However, further epidemiological studies, using repeated 
measurements to better account for the cumulative effect of the exposures on the outcomes, combined with 
experimental studies are warranted to substantiate our findings. 
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Results 
Table 1: Characteristics of the study population, Swedish AMORIS cohort 
Characteristics  Total cohort  
 (N= 14,150) 
Age at diagnosis (years)   
Mean (SD) 68 (8.0) 
N (%)  
≤49 93 (0.7) 
50-59 1953 (13.8) 
60-69 6267 (44.3) 
≥ 70 5837 (41.3) 
    
CCI  
0 10776 (76.2) 
1 1755 (12.4) 
2 1056 (7.5) 
3+ 453 (3.2) 
Missing 110 (0.8) 
  
Education   
N (%)  
High 4396 (31.1) 
Intermediate 5843 (41.3) 
Low 3698 (26.1) 
Missing 213 (1.5) 
  
Follow-up time 
Mean (SD) 
 
4.0 (3.0) 
    
Interval time between measurement 
taken on entry and prostate cancer 
diagnosis (years) 
Mean (SD) 14 (4.5) 
  
Glucose (mmol/L)   
Mean (SD) 5.2 (1.2)  
N (%)  
<5.60 11155 (78.8) 
5.6-6.9 2455 (17.4) 
>6.9 540 (3.8) 
    
Triglycerides (mmol/L)   
Mean (SD) 1.6 (1.2) 
N (%)  
<1.70 9460 (66.9) 
1.70-2.24 2384 (16.9) 
≥2.25 2306 (16.3) 
  
Total cholesterol (mmol/L)   
Mean (SD) 5.9 (1.0) 
N (%)  
<5.18 3293 (23.3) 
5.18-6.19 5378 (38.0) 
>6.19 5479 (38.7) 
    
Fasting status   
N (%)  
Fasting 8485 (60.0) 
Non-fasting 5665 (40.0) 
    
Prostate cancer risk categories   
N (%)  
Low risk 4432 (31.3) 
Intermediate risk 3988 (28.2 ) 
High risk 3226 (22.8) 
Regional/distant metastatic 2160 (15.3) 
Missing 344 (2.4) 
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Vital statistics  
N (%)  
Alive 10927 (77.2) 
All deaths 3223 (22.8) 
Prostate cancer deaths 1473 (10.4) 
CVD deaths 722 (5.1) 
Other deaths  1028 (7.3) 
• Abbreviations: N= number, CCI= Charlson comorbidity index, CVD= cardiovascular disease
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Table 2: Adjusted hazard ratios (HRs) and 95% CI for the association of serum glucose, triglycerides and total cholesterol levels with risk of overall, 
and cause-specific death among men with newly diagnosed prostate cancer, Swedish AMORIS cohort, (N=14150) 
   Overall death Prostate cancer death CVD death Other death 
  
Person-years No. of 
deaths 
HR (95% CI) No. of 
deaths 
HR (95% CI) HR (95% CI)* No. of 
deaths 
 HR (95% CI) No. of deaths HR (95% CI) 
Glucose (mmol/L)           
<5.60 60355 2370 1.00 (Ref) 1106 1.00 (Ref) 1.00 (Ref) 553 1.00 (Ref) 731 1.00 (Ref) 
5.6-6.9 10652 656 1.16 (1.05-1.27) 291 1.15 (1.00-1.32) 1.08 (0.94-1.24) 142 1.06 (0.87-1.29) 223 1.24 (1.06-1.46) 
>6.9 2303 197 1.45 (1.24-1.71) 76 1.29 (1.00-1.67) 1.10 (0.85-1.43) 47 1.47 (1.06-2.04) 74 1.66 (1.27-2.18) 
P for trend   <0.01  0.01 0.22  0.05  <0.01 
Quartiles (mmol/L)           
≤4.5 17200 596 1.00 (Ref) 266 1.00 (Ref) 1.00 (Ref) 150 1.00 (Ref) 180 1.00 (Ref) 
4.6-4.8 14983 798 1.02 (0.91-1.14) 380 1.12 (0.95-1.32) 1.10 (0.93-1.30) 169 0.85 (0.68-1.09) 249 1.00 (0.81-1.22) 
4.9-5.4 22563 853 1.02 (0.92-1.13) 396 1.13 (0.97-1.32) 1.08 (0.93-1.26) 188 0.89 (0.72-1.09) 269 0.98 (0.82-1.18) 
≥5.5 18564 976 1.19 (1.08-1.32) 431 1.27 (1.09-1.48) 1.19 (1.02-1.39) 215 0.95 (0.77-1.17) 330 1.28 (1.07-1.53) 
P for trend   <0.01  <0.01 0.04  0.76  0.01 
Triglycerides (mmol/L)           
<1.70 50150 2104 1.00 (Ref) 980 1.00 (Ref) 1.00 (Ref) 461 1.00 (Ref) 663 1.00 (Ref) 
1.70-2.24 11624 556 1.01 (0.92-1.12) 233 0.94 (0.81-1.09) 0.93 (0.80-1.08) 128 1.18 (0.96-1.44) 195 1.03 (0.86-1.23) 
≥2.25 11535 563 1.12 (1.01-1.24) 260 1.06 (0.91-1.23) 1.02 (0.88-1.18) 133 1.24 (1.00-1.53) 170 1.13 (0.94-1.35) 
P for trend    0.04  0.65 0.96   0.03   0.21 
Quartiles (mmol/L)           
≤0.8 17590 620 1.00 (Ref) 301 1.00 (Ref) 1.00 (Ref) 137 1.00 (Ref) 182 1.00 (Ref) 
0.9-1.2 14757 829 1.13 (1.01-1.26) 369 1.11 (0.94-1.30) 1.02 (0.87-1.20) 182 1.12 (0.88-1.43) 278 1.21 (1.00-1.47) 
1.3-1.8 20416 891 1.18 (1.06-1.30) 403 1.16 (1.00-1.34) 1.09 (0.94-1.26) 200 1.32 (1.06-1.64) 288 1.13 (0.94-1.36) 
≥1.9 20547 883 1.22 (1.10-1.36) 400 1.14 (0.97-1.34) 1.08 (0.92-1.26) 203 1.38 (1.10-1.74) 280 1.88 (1.06-1.55) 
P for trend   <0.01  0.09 0.27  <0.01  <0.01 
Total cholesterol 
(mmol/L) 
 
  
  
     
<5.18 17469 699 1.00 (Ref) 323 1.00 (Ref) 1.00 (Ref) 135 1.00 (Ref) 241 1.00 (Ref) 
5.18-6.19 28109 1238 0.99 (0.90-1.08) 561 0.97 (0.84-1.11) 0.94 (0.82-1.08) 279 1.17 (0.95-1.45) 388 0.91 (0.77-1.08) 
>6.19 27731 1286 1.01 (0.92-1.12) 589 1.01 (0.88-1.16) 1.00 (0.87-1.15) 308 1.30 (1.05-1.60) 399 0.86 (0.73-1.01) 
P for trend   0.74  0.80 0.90  0.01  0.08 
Quartiles (mmol/L)           
≤5.10 17469 699 1.00 (Ref) 323 1.00 (Ref) 1.00 (Ref) 135 1.00 (Ref) 241 1.00 (Ref) 
5.2-5.8 16810 860 0.98 (0.88-1.09) 387 0.96(0.82-1.13) 0.93 (0.80-1.09) 198 1.21 (0.96-1.54) 275 0.87 (0.73-1.05) 
5.9-6.5 18553 837 1.01 (0.91-1.12) 399 1.02 (0.88-1.18) 1.03 (0.89-1.19) 189 1.19 (0.95-1.50) 249 0.90 (0.75-1.07) 
≥6.60 20478 827 1.00 (0.91-1.11) 364 0.97 (0.84-1.13) 0.94 (0.81-1.09) 200 1.29 (1.03-1.61) 263 0.89 (0.74-1.06) 
P for trend   0.81  0.92 0.69  0.04  0.25 
• Abbreviations: CVD= cardiovascular disease 
• All models were adjusted for educational level, CCI, fasting status and mutually adjusted for glucose, triglycerides, and total cholesterol  
• * Adjusted for the abovementioned covariates plus prostate cancer risk category 
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Table 3: Adjusted sub-hazard ratio (SHR) and 95% CI for the associations between serum 
glucose, triglycerides and total cholesterol levels and risk of prostate cancer death among men 
with newly diagnosed prostate cancer, Swedish AMORIS cohort (N=14150) 
  Adjusted SHR (95% CI) 
Glucose (mmol/L)  
<5.6 1.00 (Ref) 
5.6-6.9  1.14(0.99-1.31) 
>6.9 1.18 (0.90-1.54) 
P for trend 0.04 
Quartiles  (mmol/L)  
≤4.5 1.00 (Ref) 
4.6-4.8 1.13 (0.93-1.33) 
4.9-5.4 1.14 (0.98-1.32) 
≥5.5 1.26 (1.08-1.46) 
P for trend <0.01 
Triglycerides (mmol/L)  
<1.70 1.00 (Ref) 
1.70-2.24 0.91 (0.78-1.06) 
≥2.25 1.02 (0.88-1.19) 
P for trend 0.96 
Quartiles  (mmol/L)  
≤0.8 1.00 (Ref) 
0.9-1.2 1.04 (0.88-1.22) 
1.3-1.8 1.11 (0.96-1.29) 
≥1.90 1.07 (0.91-1.25) 
P for trend 0.32 
Total cholesterol (mmol/L)  
<5.18 1.00 (Ref) 
5.18-6.19 0.97 (0.84-1.11) 
>6.19 1.01 (0.87-1.16) 
P for trend 0.85 
Quartiles  (mmol/L)  
≤5.1 1.00 (Ref) 
5.2-5.8 0.95 (0.82-1.12) 
5.9-6.5 1.03 (0.89-1.20) 
≥6.6 0.96 (0.83-1.12) 
 P for trend 0.88 
• Models were adjusted for educational level, CCI, fasting status and mutually adjusted for glucose, triglycerides, and total cholesterol  
• Abbreviation: SHR- sub-distribution hazard ratio 
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Table 4: Adjusted hazard ratios (HRs) and 95% CI for the associations between prostate cancer death and quartiles of serum glucose, triglycerides and total 
cholesterol by prostate cancer risk categories among men with newly diagnosed prostate cancer, Swedish AMORIS cohort (N=14150) 
  
No. of 
events 
Low risk  No. of 
events 
Intermediate risk No. of 
events 
High risk No. of 
events 
Regional/distant 
Metastatic 
P for interaction 
      HR (95%CI)    
Glucose (mmol/L)          
≤4.5 10 1.00 (ref) 29 1.00 (ref) 59 1.00 (ref) 169 1.00 (ref)  
4.6-4.8 19 3.43 (1.36-8.69) 37 1.17 (0.70-1.98) 99 1.07 (0.76-1.49) 227 1.09 (0.88-1.35) 0.21 
4.9-5.4 10 1.53 (0.57-4.08) 29 1.04 (0.64-1.70) 93 1.15 (0.85-1.56) 261 1.02 (0.84-1.23)  
≥5.5 12 2.19 (0.84-5.71) 44 1.15 (0.70-1.89) 108 1.14 (0.83-1.54) 265 1.19 (0.98-1.46)  
P for trend  0.49  0.71  0.37  0.14  
Triglycerides (mmol/L)          
≤0.8 11 1.00 (ref) 29 1.00 (ref) 69 1.00 (ref) 191 1.00 (ref)  
0.9-1.2 11 2.13 (0.94-4.81) 39 1.03 (0.61-1.72) 92 1.25 (0.91-1.72) 230 0.92 (0.75-1.13) 0.37 
1.3-1.8 14 1.57 (0.71-3.50) 46 1.07 (0.66-1.72) 93 1.03 (0.75-1.41) 249 1.09 (0.90-1.32)  
≥1.90 12 0.98 (0.38-2.53) 25 0.93 (0.56-1.56) 105 1.23 (0.89-1.68) 252 1.02 (0.83-1.24)  
P for trend  0.88  0.85  0.40  0.50  
Total cholesterol (mmol/L)          
≤5.1 13 1.00 (ref) 34 1.00 (ref) 82 1.00 (ref) 197 1.00 (ref)  
5.2-5.8 14 1.11 (0.51-2.40) 41 1.03 (0.62-1.71) 102 1.07 (0.78-1.47) 232 0.91 (0.74-1.11) 0.23 
5.9-6.5 15 1.08 (0.50-2.33) 34 0.89 (0.54-1.46) 85 0.96 (0.70-1.31) 262 1.06 (0.88-1.28)  
≥6.6 9 0.63 (0.27-1.51) 30 1.11 (0.69-1.80) 90 1.05 (0.77-1.42) 231 0.87 (0.72-1.05)  
P for trend  0.32  0.79  0.94  0.33  
* All models were adjusted for educational level, CCI, fasting status and mutually adjusted for glucose, triglycerides, total cholesterol  
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Supplementary material 1 
Table S1: Comparison of characteristics between included and excluded participants, Swedish AMORIS 2 
cohort 3 
Characteristics  Included (N= 14,150) Excluded (N=8986) 
Age at diagnosis (years)   
Mean (SD) 68 (8.0) 69 (8.3) 
   
CCI   
N (%)   
0 10776 (76.2) 6609 (73.5) 
1 1755 (12.4) 1199 (13.3) 
2 1056 (7.5) 675 (7.5) 
3+ 453 (3.2) 434 (4.8) 
Missing 110 (0.8) 69 (0.8) 
    
Education   
N (%)   
High 4396 (31.1) 2427 (27.0) 
Intermediate 5843 (41.3) 3538 (39.3) 
Low 3698 (26.1) 2553 (28.4) 
Missing 213 (1.5) 468 (5.2) 
   
Glucose (mmol/L)   
Mean (SD) 5.2 (1.2)  5.2 (1.3) 
    
Triglycerides (mmol/L)   
Mean (SD) 1.6 (1.2) 1.5 (1.0) 
   
Total cholesterol (mmol/L)   
Mean (SD) 5.9 (1.0) 5.9 (1.1) 
   
Vital status   
Alive 10927 (77.2) 5683 (63.2) 
All deaths 3223 (22.8) 3303 (36.7) 
Prostate cancer deaths 1473 (10.4) 1275 (14.2) 
CVD deaths 722 (5.1) 735 (8.2) 
Other deaths  1028 (7.3) 1293 (14.4) 
• Abbreviations: N= number 4 
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Table S2: Adjusted hazard ratios (HRs) and 95% CI for the association between overall, and cause-specific 18 
death among Swedish men with fasting glucose, triglycerides and total cholesterol measurements. 19 
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  Overall death Prostate cancer death CVD death Other death 
  
No. of 
deaths 
HR (95% CI) No. of 
deaths 
HR (95% CI) No. of 
deaths 
 HR (95% CI) No. of 
deaths 
HR (95% CI) 
Glucose (mmol/L)         
<5.60 1422 1.00 (Ref) 682 1.00 (Ref) 318 1.00 (Ref) 422 1.00 (Ref) 
5.6-6.9 382 1.16 (1.03-1.31) 162 1.10 (0.92-1.32) 79 0.88 (0.67-1.16) 121 1.48 (1.21-1.80) 
>6.9 108 1.53 (1.23-1.90) 44 1.56 (1.12-2.16) 27 1.56 (1.01-2.40) 37 1.52 (1.03-2.25) 
P for trend  <0.01  0.01  0.44  <0.01 
Quartiles  (mmol/L)         
≤4.5 334 1.00 (Ref) 162 1.00 (Ref) 78 1.00 (Ref) 94 1.00 (Ref) 
4.6-4.8 484 1.02 (0.88-1.19) 231 1.06 (0.86-1.30) 104 0.95 (0.70-1.30) 149 1.02 (0.78-1.33) 
4.9-5.4 528 0.99 (0.87-1.12) 253 1.03 (0.85-1.25) 116 0.93 (0.71-1.23) 159 0.96 (0.76-1.22) 
≥5.5 566 1.19 (1.04-1.36) 242 1.17 (0.96-1.42) 126 0.98 (0.74-1.30) 198 1.40 (1.11-1.77) 
P for trend  0.02  0.16  0.87  <0.01 
Triglycerides 
(mmol/L)   
  
    
<1.70 1321 1.00 (Ref) 628 1.00 (Ref) 283 1.00 (Ref) 410 1.00 (Ref) 
1.70-2.24 302 1.01 (0.88-1.15) 122 0.99 (0.82-1.20) 68 1.17 (0.89-1.53) 102 0.93 (0.73-1.19) 
≥2.25 289 1.17 (1.03-1.34) 128 1.08 (0.89-1.32) 73 1.32 (1.01-1.75) 88 1.20 (0.95-1.53) 
P for trend  0.04  0.50  0.04  0.25 
Quartiles  (mmol/L)         
≤0.8 423 1.00 (Ref) 219 1.00 (Ref) 89 1.00 (Ref) 115 1.00 (Ref) 
0.9-1.2 529 1.22 (1.07-1.40) 242 1.13 (0.93-1.37) 107 1.19 (0.88-1.62) 180 1.44 (1.14-1.82) 
1.3-1.8 501 1.24 (1.09-1.41) 220 1.19 (0.99-1.43) 118 1.50 (1.13-1.97) 163 1.19 (0.94-1.50) 
≥1.90 459 1.30 (1.14-1.50) 207 1.19 (0.98-1.47) 110 1.51 (1.12-2.04) 142 1.38 (1.07-1.76) 
P for trend  <0.01  0.06  <0.01  0.06 
Total cholesterol 
(mmol/L)   
  
    
<5.18 408 1.00 (Ref) 195 1.00 (Ref) 69 1.00 (Ref) 144 1.00 (Ref) 
5.18-6.19 717 0.92 (0.82-1.04) 332 0.88 (0.74-1.05) 160 1.29 (0.97-1.72) 225 0.86 (0.66-1.01) 
>6.19 787 0.93 (0.82-1.05) 361 0.89 (0.75-1.07) 195 1.31 (1.01-1.77) 231 0.79 (0.64-0.98) 
P for trend  0.29  0.28  0.07  0.04 
Quartiles  (mmol/L)         
≤5.1 408 1.00 (Ref) 195 1.00 (Ref) 69 1.00 (Ref) 144 1.00 (Ref) 
5.2-5.8 500 0.89 (0.73-1.08) 231 0.89 (0.73-1.08) 116 1.42 (1.05-1.93) 153 0.75 (0.59-0.95) 
5.9-6.5 500 0.92 (0.76-1.11) 242 0.92 (0.76-1.11) 112 1.16 (0.85-1.58) 146 0.86 (0.69-1.09) 
≥6.6 504 0.86 (0.71-1.03) 220 0.86 (0.71-1.03) 127 1.37 (1.03-1.84) 157 0.79 (0.63-0.99) 
P for trend  0.25  0.16  0.13  0.12 
         
         
• Abbreviations: Prostate cancer= prostate cancer, CVD= cardiovascular disease 20 
• Models were adjusted for age, educational level, CCI and mutually adjusted for glucose, triglycerides, and total cholesterol  21 
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